Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Dow
Express Scripts
Fish and Richardson
Boehringer Ingelheim
US Department of Justice
Moodys
Argus Health
Baxter

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AZILECT

« Back to Dashboard

Clinical Trials for Azilect

Trial ID Title Status Sponsor Phase Summary
NCT00399477 A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease Completed Teva Neuroscience, Inc. Phase 4 Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: - Group 1 Patients using Azilect and no other therapy. - Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
NCT00696215 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status Istanbul University Phase 4 The objective of the study is to assess the effects of rasagiline on cognitive functions in patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by selected neuropsychological tests representing each cognitive domain.
NCT00955604 Azilect + Antidepressant Chart Review Completed Teva Pharmaceutical Industries N/A To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD patients receiving antidepressants, but not rasagiline.
NCT01007630 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status Teva Neuroscience, Inc. Phase 4 A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Azilect

Condition Name

Condition Name for Azilect
Intervention Trials
Parkinson's Disease 14
Parkinson Disease 3
Parkinson´s Disease 1
Serotonin Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Azilect
Intervention Trials
Parkinson Disease 20
Cognition Disorders 2
Motor Neuron Disease 1
Serotonin Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Azilect

Trials by Country

Trials by Country for Azilect
Location Trials
United States 25
Germany 4
China 3
Turkey 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Azilect
Location Trials
New York 3
Florida 3
Pennsylvania 2
Ohio 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Azilect

Clinical Trial Phase

Clinical Trial Phase for Azilect
Clinical Trial Phase Trials
Phase 4 11
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Azilect
Clinical Trial Phase Trials
Completed 14
Terminated 3
Unknown status 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Azilect

Sponsor Name

Sponsor Name for Azilect
Sponsor Trials
Teva Pharmaceutical Industries 5
Teva Neuroscience, Inc. 4
H. Lundbeck A/S 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Azilect
Sponsor Trials
Industry 19
Other 15
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Teva
Covington
Fuji
Mallinckrodt
Fish and Richardson
Cerilliant
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.